Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 178

Sort by

Sort Order Select

Journal Articles

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Blood (2025) 146 (Supplement 1): 485.

https://doi.org/10.1182/blood-2025-485

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”

Blood (2025) 146 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2025-1021

Published: 2025

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study

David Ross, Andrew Wilson, Tara Cochrane, William Stevenson, James Liang, Marco Brociner, Francesca Palandri, Stephen Larsen, Merit Hanna, Alessandro Maria Vannucchi, Kristen Pettit, Natalia Curto-Garcia, Harinder Gill, Uche Okoro, Jonas Jutzi, Patricia Marinello, Monia Marchetti

Blood (2025) 146 (Supplement 1): 2033.

https://doi.org/10.1182/blood-2025-2033

Published: 2025

Journal Articles

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

Andrew Kuykendall, Francesca Palandri, Bella Vo, Fulya Sen Nikitas, Nicholas Meader, Shiyuan Zhang, Tom (sizhu) Liu, Shuang Wang, Gautam Sajeev, Mirko Fillbrunn, James Signorovitch, Jasmine Sahni, Dwaipayan Patnaik, Aaron Gerds

Blood (2025) 146 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2025-2031

Published: 2025

Journal Articles

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Francesca Palandri, Nicolaas Schaap, Jérôme Rey, Nikolas Von Bubnoff, Andreas Reiter, Juan Carlos Hernandez Boluda, Timothy Devos, Bethan Psaila, Donal McLornan, Catherine Ellis, Fulya Sen Nikitas, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Stephen Oh

Blood (2025) 146 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2025-2023

Published: 2025

Journal Articles

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Vikas Gupta, Francesca Palandri, Jean-Jacques Kiladjian, Bethan Psaila, Bella Vo, Jessica Lim, Fulya Sen Nikitas, Shiyuan Zhang, Tom (sizhu) Liu, Catherine Ellis, Jasmine Sahni, Dwaipayan Patnaik, Stephen Oh, Ruben Mesa

Blood (2025) 146 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2025-3809

Published: 2025

Journal Articles

Refining thrombotic risk stratification in essential thrombocythemia: Impact of european leukemia net clinical signs and symptoms in patients treated with hydroxyurea

Francesca Palandri, Filippo Branzanti, Alessandra Dedola, Chiara Sartor, Pier Luigi Zinzani

Blood (2025) 146 (Supplement 1): 3807.

https://doi.org/10.1182/blood-2025-3807

Published: 2025

Journal Articles

Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study

Blood (2025) 146 (Supplement 1): 3806.

https://doi.org/10.1182/blood-2025-3806

Published: 2025

Journal Articles

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Blood (2025) 146 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2025-3795

Published: 2025

Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Blood (2025) 146 (Supplement 1): 910.

https://doi.org/10.1182/blood-2025-910

Published: 2025

Journal Articles

Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial

Ciro Rinaldi, David Ross, Lynette Chee, Alessandra Iurlo, Chun Teh, Francesca Palandri, Maria Laura Fox, Jennifer O'Sullivan, Marco Brociner, Jen Salstrom, Xin Tong, Varsha Sundaresan, Leopold Sellner, Katsuhiro Togami, Claire Harrison

Blood (2025) 146 (Supplement 1): 909.

https://doi.org/10.1182/blood-2025-909

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

A phase II Study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment – fraction Study / IKF051 / gsg-MPN-006

Susanne Isfort, Nikolas Von Bubnoff, Haifa Kathrin Al-Ali, Heiko Becker, Frank Stegelmann, Thorsten Götze, Philipp le Coutre, Martin Griesshammer, Adrian Schwarzer, Luisa Wohn, Salah-Eddin Al-Batran, Johanna Riedel, Francesca Palandri, Kirsi Manz, Andreas Hochhaus, Konstanze Döhner, Florian Heidel

Blood (2025) 146 (Supplement 1): 5589.

https://doi.org/10.1182/blood-2025-5589

Published: 2025

Journal Articles

Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera

Aniket Bankar, Andrew Kuykendall, Naveen Pemmaraju, Kristen Pettit, Joseph Shatzel, Alessandro Lucchesi, Valentín García Gutiérrez, Harinder Gill, Joseph Scandura, Francesca Palandri, Matthew Reaney, Cristina Ivanescu, Christina Daskalopoulou, Phil Dinh, Sarita Khanna, Suneel Gupta, Arturo Molina, David Cella

Blood (2025) 146 (Supplement 1): 5588.

https://doi.org/10.1182/blood-2025-5588

Published: 2025

Journal Articles

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal McLornan, Steffen Koschmieder, Juan Carlos Hernandez Boluda, Catherine Ellis, Tom (sizhu) Liu, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Vikas Gupta

Blood (2025) 146 (Supplement 1): 5581.

https://doi.org/10.1182/blood-2025-5581

Published: 2025

Journal Articles

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

Raajit Rampal, Prithviraj Bose, Vikas Gupta, Francesca Palandri, Shiyuan Zhang, Jessica Lim, Fulya Sen Nikitas, Tom (sizhu) Liu, Jasmine Sahni, Catherine Ellis, Dwaipayan Patnaik, Florian Heidel, Francesco Passamonti

Blood (2025) 146 (Supplement 1): 5579.

https://doi.org/10.1182/blood-2025-5579

Published: 2025

Journal Articles

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Blood (2025) 146 (Supplement 1): 5574.

https://doi.org/10.1182/blood-2025-5574

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM

Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib

Refining thrombotic risk stratification in essential thrombocythemia: Impact of european leukemia net clinical signs and symptoms in patients treated with hydroxyurea

Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

A phase II Study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment – fraction Study / IKF051 / gsg-MPN-006

Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1

INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only